Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > Employee reviews
View:
Post by langosta on Jun 17, 2022 2:10pm

Employee reviews

Some reviews from INDEED: Some good, some not so good.


https://ca.indeed.com/cmp/Theralase/reviews?fcountry=CA&floc=Toronto%2C+ON
Comment by Gooseybear on Jun 19, 2022 8:11am
Employee reviews of Theralase on Glass Door mentioned paranoid husband and wife management team who micromanage and don't understand how to run a real business. I think most of our TLTF longholders wouldn't find this surprising.
Comment by Oilminerdeluxe on Jun 19, 2022 9:31am
Just because you are paranoid doesn't mean they aren't out to get ya! Hopes for a great week leading up to the agm.
Comment by Longholder99 on Jun 19, 2022 10:01am
Disgruntled employees who get dismissed for various reasons like to bad mouth their former boss. Like the guy who got himself sued by Roger and lost a nice bit of money in court if I recall. Not surprised.
Comment by gebremeskel on Jun 19, 2022 12:52pm
How many cancer drugs have you brought to market Gooseybear? If TLD1433 gets approval to commercialize we'll all be rich and Theralase will become famous as "the little company that could" Longs are long for a reason. It may be a little early for gratitude but attacking the goose you are hoping will gift you a golden egg is both imprudent and churlish.
Comment by ScienceFirst on Jun 19, 2022 8:33pm
Not an issue.   TLT management brought us to a Breakthrough designation candidate, while battling against big pharmas unlimited resources, while being slowed by COVID-19, etc ....  Not bad at all.  Employees don't take risks, don't innovate.  They execute. It's not this fired employee that would have had the crazy idea to bring PDT/PDC to bedside and ...more  
Comment by FGPstock on Jun 19, 2022 10:36pm
Ben, pretty sure everyone at TLT is an employee. Using out money to take risk. We owe it all to Sheeri, who hot a horrible deal, imo...
Comment by ScienceFirst on Jun 20, 2022 8:14am
FGPstock ... lolll  Pretty simplistic and arrogant view that even Prof. McFarland would not agree on.  A molecule alone is nothing.  Go ask Prof McFarland's  peers (Prof Glazier, Prof. Gasser, etc ...) that have come up with similar molecules but that never found a multidisciplinary team to make the whole thing work. We owe it all to Sherri?  Not really, but she' ...more  
Comment by langosta on Jun 20, 2022 8:50am
Great post SF.
Comment by Legit62 on Jun 20, 2022 9:06am
Great post SF, right to the point and agree about the April 5 drop, short sighted investors(probably day traders trying to make a buck) and shorts, our day will come soon
Comment by ScienceFirst on Jun 20, 2022 9:08am
FGPStock ... Your post was one of a short-sighted guy.  Sad that you missed another opportunity to be more appreciative of TLT's work.  Take a look and notice the multi-disciplinary work. Not the success of just a chemist.  Notice also that they are still in the mice animal model. And notice how Roger was a visionary and how Theralase is year ahead of them. https://amp ...more  
Comment by Eoganacht on Jun 20, 2022 12:34pm
Thanks for that, ScienceFirst. That's very interesting research. But, like you say, it's very early days and the procedure has certain limitations. They attach a specific anti-body-like molecule to a PS, and the conjugate attaches exclusively to target receptors that are overexpressed in EGFR positive GBM cancer cells. They then irradiate with NIR light and besides killing the cancer ...more  
Comment by Infinity on Jun 20, 2022 12:31am
Goosey,  I would not base my opinion of a company entirely on the biased views of employees or ex-employees.  Granted, some of the ex-employees may have left the company for very good reasosns. Some would have been let go or laid off during Covid, again for very good reasons by the management.  The employees reviews via Indeed is not without its drawbacks.  If you look at the ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250